Search clinical trials for: Dengue Vaccine

Total 10115 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Puerto Rico, Brazil, Honduras, Mexico
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

GLS-5700 in Dengue Virus Seropositive Adults

Healthy | Zika

Puerto Rico
University of Maryland, Baltimore
United States Army Medical Materiel Development Activity; Medical Technology...

Completed

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

Dengue

United States
Takeda

Completed

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Dengue Fever

United States
U.S. Army Medical Research and Development Command

Active, not recruiting

Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine

Dengue Virus

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

Dengue

United States
Takeda

Completed

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

Dengue Fever

United States
Takeda

Completed

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Dengue

United States
Albert B. Sabin Vaccine Institute
Pan American Health Organization; State of Parana/Health Department of Parana; Ministry of Health of Brazil and other collaborators

Completed

Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil

Dengue

Brazil
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health; University of Vermont

Completed

Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh

Dengue

Bangladesh
GlaxoSmithKline
Ministry of Health, Sri Lanka

Completed

A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia

Dengue

Sri Lanka
Takeda

Completed

Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

Dengue Fever

Philippines, Dominican Republic, Panama
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge

Dengue

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

Dengue

United States
Takeda

Completed

Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore

Dengue Fever

Singapore
Takeda

Completed

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)

Dengue

Mexico
Medigen Vaccine Biologics Corp.

Completed

A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan

Dengue

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
Takeda

Completed

Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

Dengue Fever

United States
Takeda

Completed

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

Healthy

United States
Sanofi

Completed

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

United States
GlaxoSmithKline

Completed

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

Dengue

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (DPIV-001)

Dengue Fever

United States
Butantan Institute
Fundação de Amparo à Pesquisa do Estado de São Paulo; Banco Nacional de Desenvolvimento... and other collaborators

Unknown

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Dengue

Brazil
Merck Sharp & Dohme LLC

Completed

Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

Dengue
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand

Dengue

Thailand
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children

Dengue

Thailand
U.S. Army Medical Research and Development Command

Completed

TDENV PIV and LAV Dengue Prime-boost Strategy

Dengue

United States
Inviragen Inc.

Completed

Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever

Dengue Fever

Colombia
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

Dengue

United States
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

Dengue

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

Dengue

Thailand
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Shock Syndrome

Puerto Rico
U.S. Army Medical Research and Development Command
United States Army Medical Materiel Development Activity

Completed

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

Dengue

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand

Dengue

Thailand
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Withdrawn

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine

Dengue

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR); Naval Medical Research Center; Vic...

Completed

Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease (TVDV)

Dengue Fever | Dengue Disease

United States
National Institute of Allergy and Infectious Diseases...
Merck Sharp & Dohme LLC

Completed

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

Dengue

United States
U.S. Army Medical Research and Development Command

Completed

Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease (DENV-1 PIV)

Dengue Fever

United States

3

Subscribe